Pulmonary Toxicities in Pediatric Patients Treated With Total Body Irradiation Using the Lateral Opposed Fields

Natalie Boyce1, Safia Ahmed2, W Scott Harmsen3

  • 1Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.

PubMed

Insights

Pulmonary toxicity (PT) occurred in 33% of pediatric patients after total body irradiation (TBI). Preventing graft-versus-host disease (GVHD) and using low TBI dose rates can reduce PT risk and improve survival.

Area of Science:

  • Pediatric oncology
  • Radiation oncology
  • Hematopoietic stem cell transplantation

Background:

  • Pulmonary toxicity (PT) is a significant concern following total body irradiation (TBI) in pediatric patients undergoing stem cell transplantation.
  • Understanding the incidence and risk factors for PT is crucial for improving patient outcomes.

Purpose of the Study:

  • To determine the incidence and associated factors of pulmonary toxicity (PT) in pediatric patients treated with total body irradiation (TBI) using a lateral opposed fields technique.
  • To evaluate the impact of PT on overall survival (OS).

Main Methods:

  • Retrospective review of medical records for 61 pediatric patients (≤21 years) treated with TBI between 1993-2017.
  • Recording incidences of PT, graft-versus-host disease (GVHD), and other toxicities.
  • Analyzing associations between PT and clinical variables using chi-square tests and estimating overall survival (OS) with Kaplan-Meier methods.

Main Results:

  • Three-year OS was 65%. PT occurred in 33% of patients.
  • A higher PT rate was observed in patients with GVHD (65% vs. 35%, p ≤ 0.01).
  • Higher TBI dose rates increased PT risk (HR = 1.9, p = 0.04), and PT was associated with inferior OS (HR = 3.4, p = 0.01).

Conclusions:

  • The cohort treated with low dose rate TBI (4.0-10 cGy/min) experienced an acceptable PT incidence.
  • PT, noninfectious PT, and pneumonitis significantly correlated with reduced survival.
  • Future strategies should focus on preventing GVHD and utilizing low TBI dose rates to mitigate PT and improve outcomes.
Abstract